Mode
Text Size
Log in / Sign up

Clinical Trial Search

Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.

Phase
Intervention
Population
Results posted

30 closest matches · ranked by relevance

Phase 2 N=41 Linezolid to Treat Extensively-Drug Resistant Tuberculosis

Pulmonary Tuberculosis · Multidrug Resistant Tuberculosis · Extensively Drug Resistant Tuberculosis
Primary: Number of Patients Converted to Sputum Culture Negative in Each Arm, With Data Censored at 4 Months. — 15; 7 participants
National Institute of Allergy and Infectious… Results Feb 2014 65.8% serious AE View details

Phase 2 N=196 Improving Retreatment Success (IMPRESS)

Recurrent Tuberculosis
Primary: Sputum Culture Conversion Rates at Week 8 and Month 6 Post Tuberculosis Treatment Initiation — 78; 73; 84; 92 Participants — p=0.46
Centre for the AIDS Programme of Research in… Results Aug 2019 19.9% serious AE View details

Phase 3 N=284 Shortening Treatment by Advancing Novel Drugs

Tuberculosis, Pulmonary, Drug Sensitive · Tuberculosis, Pulmonary, Multi Drug-resistant
Primary: Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population) — 38…
Global Alliance for TB Drug Development Results Mar 2019 8.8% serious AE View details

Phase 3 N=394 Tuberculosis Treatment Shortening Trial

Tuberculosis
Primary: Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-tuberculosis (TB) Treatment - Intention-to-treat — 13; 3 Participants
National Institute of Allergy and Infectious… Results Jan 2010 10.4% serious AE View details

Phase 2 N=481 A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

Tuberculosis, Pulmonary · Tuberculosis, Multidrug Resistant · Extensively Drug-Resistant Tuberculosis
Primary: Percentage of Participants Who Achieved Sputum Culture Conversion (SCC) Using the Mycobacteria Growth Indicator Tube (MGIT) System — 45.4; 41.9; 29.6 percentage of…
Otsuka Pharmaceutical Development &… Results Dec 2021 10.4% serious AE View details

Phase 2 N=69 Essentiality of INH in TB Therapy

Tuberculosis
Primary: Daily Decrease in log10 Transformed Colony-forming Unit (CFU) Counts Per ml Sputum From Baseline (Study Treatment Initiation) to Day 14 — 0.134; 0.096; 0.136; 0.119…
Advancing Clinical Therapeutics Globally for… Results Apr 2017 4.4% serious AE View details

Phase 2 N=240 A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.

Tuberculosis
Primary: Rate of Change in Time to Sputum Culture Positivity (TTP) Over 8 Weeks in the Mycobacterial Growth Indicator Tube (MGIT) System — 4.878; 5.182; 4.046; 5.194 percentage…
Global Alliance for TB Drug Development Results Jul 2019 6.3% serious AE View details